























# Research Questions

---

- ☐ Pathogenesis? Specific mediators
- ☐ Autoimmune trigger? (antithyroid autoantibodies)
- ☐ Prevention? (often post-viral or post-infectious)
- ☐ Pharmacogenomics/predictive responders
- ☐ Duration of treatment?
- ☐ Molecular Mimicry?

# Clinical Update: Omalizumab (Xolair)

- ❑ Humanized monoclonal anti-IgE (Fc)
- ❑ FDA approval asthma 2003, CIU 2014
- ❑ Dosed as 300mg every 4 weeks SubQ (asthma dose is based on IgE level)




Figure 2. Possible mechanisms of action of omalizumab. IgE = immunoglobulin E.